Expert perspectives on cholangiocarcinoma (CCA)

Optimising molecular profiling and the multidisciplinary team approach in cholangiocarcinoma (ESMO 2022)

Dr Angela Lamarca

Fundación Jiménez Díaz University Hospital, Spain

Disclosures

Dr Angela Lamarca:

Company/Organisation	Relationship(s)
Albireo Pharma, AstraZeneca, Boehringer Ingelheim, Boston Scientific, Eisai, GenFit, Nutricia Ipsen, QED, Roche, Servier and TransThera Biosciences	Receipt of honoraria or consultation fees
AAA, AstraZeneca, Eisai, Incyte, Ipsen, Merck, Pfizer, QED, Roche and Servier	Participation in company-sponsored speaker bureau
AAA, Bayer, Delcath, Ipsen, Mylan, Novartis, Pfizer and Sirtex	Travel, education funding
Ipsen and Roche	Research funding

This website has been created and funded by Incyte.

If you would like to request further medical information, please visit:
www.incyteglobalmedicalinformation.com